Source: firstwordpharma

Valeritas: Zealand Pharma completes the acquisition of Valeritas

Zealand Pharma (NASDAQ: ZEAL) has acquired Valeritas Holdings, Inc. (NASDAQ: VLRX), a U.S. based commercial-stage company for a cash purchase price of $23 million

Read full article »
Valeritas's Competitors | Valeritas's News | Valeritas's Financials
Stay up-to-date with the latest news on Valeritas
Est. Annual Revenue
$25-100M
Est. Employees
100-250
John Timberlake's photo - President & CEO of Valeritas

President & CEO

John Timberlake

CEO Approval Rating

85/100

Read more
Stay up-to-date with the latest news on Valeritas